weekly_roundup

BioTechSign Daily Catalyst Roundup - October 26, 2026

Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.

BiotechSign AnalysisOctober 26, 2026

Daily Biotech Catalyst Digest: October 26, 2026

ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.

Top Catalyst Scores

TickerCompanyScoreGradeStrongest Inputs
ITCIIntra-Cellular Therapies100.0Aclinical activity 100%
DCPHDeciphera Pharmaceuticals100.0Aclinical activity 100%
BGNEBeiGene Ltd100.0Apublication signal 100%, clinical activity 100%
AKBAAkebia Therapeutics87.2Aclinical activity 92%, short interest 50%
RGNXREGENXBIO Inc86.4Apublication signal 100%, clinical activity 100%, short interest 70%
SRPTSarepta Therapeutics85.9Aclinical activity 100%, short interest 70%, dilution risk 48%

Recent Grade-Change Queue

  • NTLA (Intellia Therapeutics) currently grades D with a 45.7/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, clinical activity 79%.
  • NKTR (Nektar Therapeutics) currently grades B with a 74.0/100 catalyst score. Main inputs: short interest 90%, clinical activity 75%, dilution risk 65%.
  • CELZ (Creative Medical Technology Holdings, Inc.) currently grades D with a 42.4/100 catalyst score. Main inputs: dilution risk 83%, clinical activity 33%, short interest 10%.
  • AIM (AIM ImmunoTech Inc.) currently grades D with a 37.2/100 catalyst score. Main inputs: dilution risk 75%, short interest 50%, clinical activity 46%.
  • ALLO (Allogene Therapeutics) currently grades F with a 23.9/100 catalyst score. Main inputs: publication signal 100%, dilution risk 51%, short interest 50%.
  • NRIX (Nurix Therapeutics) currently grades F with a 34.9/100 catalyst score. Main inputs: publication signal 100%, short interest 70%, clinical activity 54%.
  • GPCR (Structure Therapeutics) currently grades D with a 45.2/100 catalyst score. Main inputs: publication signal 100%, clinical activity 54%, dilution risk 27%.
  • CAPR (Capricor Therapeutics, Inc.) currently grades C with a 52.0/100 catalyst score. Main inputs: PDUFA timing 90%, short interest 90%, dilution risk 34%.

What To Watch

Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.